Incyte (INCY) Reports Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. HUM
8. KTOS
9. NVDA
10. CSCO

Go back to Incyte (INCY) Reports Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib

Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

December 11, 2021 9:00 AM EST

- Data from the CITADEL program of parsaclisib in patients with follicular, marginal zone and mantle cell lymphomas were accepted as oral presentations at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021)

- Data supported Incytes New Drug Application (NDA) for parsaclisib accepted by the U.S. FDA

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY) today announced data from three ongoing Phase 2 studies evaluating parsaclisib, an investigational novel potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3K), for the treatment of patients with... More